Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Malignant Melanoma

Free Subscription Articles published in Cancer Res Retrieve available abstracts of 98 articles: HTML format Text format

Single Articles

August 2018
1. CAPPARELLI C, Purwin TJ, Heilman SA, Chervoneva I, et al
   ErbB3 targeting enhances the effects of MEK inhibitor in wild-type BRAF/NRAS melanoma.
   Cancer Res. 2018 Aug 16. pii: 0008-5472.CAN-18-1001.
   PubMed     Text format     Abstract available
   
   
   
2. HUANG M, Qi TF, Li L, Zhang G, et al
   A targeted quantitative proteomic approach assesses the reprogramming of small GTPases during melanoma metastasis.
   Cancer Res. 2018 Aug 2. pii: 0008-5472.CAN-17-3811.
   PubMed     Text format     Abstract available
   
   
   July 2018
3. VISHNOI M, Boral D, Liu H, Sprouse ML, et al
   Targeting USP7 identifies a metastasis-competent state within bone marrow-resident melanoma CTCs.
   Cancer Res. 2018 Jul 19. pii: 0008-5472.CAN-18-0644.
   PubMed     Text format     Abstract available
   
   
   
4. SHABANEH TB, Molodtsov A, Steinberg SM, Zhang P, et al
   Oncogenic BRAFV600E governs regulatory T cell recruitment during melanoma tumorigenesis.
   Cancer Res. 2018 Jul 19. pii: 0008-5472.CAN-18-0365.
   PubMed     Text format     Abstract available
   
   
   June 2018
5. WANG L, Felts SJ, Van Keulen VP, Scheid AD, et al
   Integrative genome-wide analysis of long noncoding RNAs in diverse immune cell types of melanoma patients.
   Cancer Res. 2018 Jun 12. pii: 0008-5472.CAN-18-0529.
   PubMed     Text format     Abstract available
   
   
   May 2018
6. HUERGO ZAPICO L, Parodi M, Cantoni C, Lavarello C, et al
   NK cell editing mediates Epithelial to Mesenchymal Transition via phenotypic and proteomic changes in melanoma cell lines.
   Cancer Res. 2018 May 11. pii: 0008-5472.CAN-17-1891.
   PubMed     Text format     Abstract available
   
   
   February 2018
7. HOULES T, Gravel SP, Lavoie G, Shin S, et al
   RSK Regulates PFK-2 Activity to Promote Metabolic Rewiring in Melanoma.
   Cancer Res. 2018 Feb 12. pii: 0008-5472.CAN-17-2215.
   PubMed     Text format     Abstract available
   
   
   December 2017
8. SIMON S, Vignard V, Varey E, Parrot T, et al
   Emergence of High-Avidity Melan-A-Specific Clonotypes as a Reflection of Anti-PD-1 Clinical Efficacy.
   Cancer Res. 2017;77:7083-7093.
   PubMed     Text format     Abstract available
   
   
   
9. DIAZ-MARTINEZ M, Benito-Jardon L, Alonso L, Koetz-Ploch L, et al
   miR-204-5p and miR-211-5p contribute to BRAF inhibitor resistance in melanoma.
   Cancer Res. 2017 Dec 11. pii: 0008-5472.CAN-17-1318.
   PubMed     Text format     Abstract available
   
   
   
10. YAEGER R, Yao Z, Hyman DM, Hechtman JF, et al
    Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.
    Cancer Res. 2017;77:6513-6523.
    PubMed     Text format     Abstract available
    
    
    November 2017
11. WANG G, Mustafi S, Camarena V, Volmar CH, et al
    Vitamin C sensitizes melanoma to BET inhibitors.
    Cancer Res. 2017 Nov 27. pii: 0008-5472.CAN-17-2040.
    PubMed     Text format     Abstract available
    
    
    
12. BRIGHTON HE, Angus SP, Bo T, Roques J, et al
    New mechanisms of resistance to MEK inhibitors in melanoma revealed by intravital imaging.
    Cancer Res. 2017 Nov 27. pii: 0008-5472.CAN-17-1653.
    PubMed     Text format     Abstract available
    
    
    
13. MO X, Zhang H, Preston S, Martin K, et al
    Interferon-2; signaling in melanocytes and melanoma cells regulates expression of CTLA-4.
    Cancer Res. 2017 Nov 17. pii: canres.1615.2017.
    PubMed     Text format     Abstract available
    
    
    
14. HUA KT, Hong JB, Sheen YS, Huang HY, et al
    MicroRNA-519d promotes melanoma progression by downregulating EphA4.
    Cancer Res. 2017 Nov 1. pii: canres.1933.2017.
    PubMed     Text format     Abstract available
    
    
    October 2017
15. BLATTNER C, Fleming V, Weber R, Himmelhan BS, et al
    CCR5+ myeloid-derived suppressor cells are enriched and activated in melanoma lesions.
    Cancer Res. 2017 Oct 31. pii: canres.0348.2017.
    PubMed     Text format     Abstract available
    
    
    
16. SIERRA RA, Trillo-Tinoco J, Mohamed E, Yu L, et al
    Anti-Jagged Immunotherapy Inhibits MDSCs and Overcomes Tumor-Induced Tolerance.
    Cancer Res. 2017;77:5628-5638.
    PubMed     Text format     Abstract available
    
    
    
17. BUCSEK MJ, Qiao G, MacDonald CR, Giridharan T, et al
    beta-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy.
    Cancer Res. 2017;77:5639-5651.
    PubMed     Text format     Abstract available
    
    
    
18. COUNTER CM, Crowe MS, Greenberg DN, Brady DC, et al
    Copper Chelation Inhibits BRAFV600E-driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors.
    Cancer Res. 2017 Oct 6. pii: canres.1190.2016.
    PubMed     Text format     Abstract available
    
    
    
19. PICCO N, Sahai E, Maini PK, Anderson ARA, et al
    Integrating Models to Quantify Environment-Mediated Drug Resistance.
    Cancer Res. 2017;77:5409-5418.
    PubMed     Text format     Abstract available
    
    
    September 2017
20. LI J, Yan S, Liu Z, Zhou Y, et al
    Multiregional sequencing reveals genomic alterations and clonal dynamics in primary malignant melanoma of the esophagus.
    Cancer Res. 2017 Sep 29. pii: canres.0938.2017.
    PubMed     Text format     Abstract available
    
    
    
21. WANG JY, Liu GZ, Wilmott JS, La T, et al
    Skp2-mediated stabilization of MTH1 promotes survival of melanoma cells upon oxidative stress.
    Cancer Res. 2017 Sep 25. pii: canres.1965.2017.
    PubMed     Text format     Abstract available
    
    
    
22. NEISWENDER JV, Kortum RL, Bourque C, Kasheta M, et al
    KIT suppresses BRAFV600E-mutant melanoma by attenuating oncogenic RAS/MAPK signaling.
    Cancer Res. 2017 Sep 25. pii: canres.0473.2017.
    PubMed     Text format     Abstract available
    
    
    
23. LI P, Wuthrick E, Rappaport JA, Kraft C, et al
    GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome.
    Cancer Res. 2017;77:5095-5106.
    PubMed     Text format     Abstract available
    
    
    
24. NDOYE A, Budina-Kolomets A, Kugel CH, Webster MR, et al
    ATG5 mediates a positive feedback loop between Wnt signaling and autophagy in melanoma.
    Cancer Res. 2017 Sep 8. pii: canres.0907.2017.
    PubMed     Text format     Abstract available
    
    
    
25. DONIA M, Harbst K, van Buuren M, Kvistborg P, et al
    Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNgamma Signaling.
    Cancer Res. 2017;77:4562-4566.
    PubMed     Text format     Abstract available
    
    
    August 2017
26. YANG F, Wei J, Zhang S, Zhang X, et al
    Shrimp miR-S8 suppresses the stemness of human melanoma stem-like cells by targeting the transcription factor YB-1.
    Cancer Res. 2017 Aug 30. pii: canres.1375.2017.
    PubMed     Text format     Abstract available
    
    
    
27. ZHAO Y, Ting KK, Li J, Cogger VC, et al
    Targeting Vascular Endothelial-Cadherin in Tumor-Associated Blood Vessels Promotes T-cell-Mediated Immunotherapy.
    Cancer Res. 2017;77:4434-4447.
    PubMed     Text format     Abstract available
    
    
    
28. ABU EID R, Ahmad S, Lin Y, Webb M, et al
    Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-delta Inhibition.
    Cancer Res. 2017;77:4135-4145.
    PubMed     Text format     Abstract available
    
    
    July 2017
29. JIANG H, Rivera-Molina Y, Gomez-Manzano C, Clise-Dwyer K, et al
    Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.
    Cancer Res. 2017;77:3894-3907.
    PubMed     Text format     Abstract available
    
    
    
30. 
    Retraction: Molecular Mechanism of MART-1+/A*0201+ Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor-CTL Interaction.
    Cancer Res. 2017;77:3718.
    PubMed     Text format    
    
    
    
31. FERNANDEZ-POMA SM, Salas-Benito D, Lozano T, Casares N, et al
    Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy.
    Cancer Res. 2017;77:3672-3684.
    PubMed     Text format     Abstract available
    
    
    June 2017
32. REINHARDT J, Landsberg J, Schmid-Burgk JL, Bibiloni Ramis B, et al
    MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapy.
    Cancer Res. 2017 Jun 26. pii: canres.0395.2017.
    PubMed     Text format     Abstract available
    
    
    
33. YOUNG A, Ngiow SF, Madore J, Reinhardt J, et al
    Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis.
    Cancer Res. 2017 Jun 26. pii: canres.0393.2017.
    PubMed     Text format     Abstract available
    
    
    
34. BARTEE MY, Dunlap KM, Bartee E
    Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy.
    Cancer Res. 2017;77:2952-2963.
    PubMed     Text format     Abstract available
    
    
    May 2017
35. 
    Correction: Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.
    Cancer Res. 2017;77:2770.
    PubMed     Text format    
    
    
    
36. PRAT A, Navarro A, Pare L, Reguart N, et al
    Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma and melanoma.
    Cancer Res. 2017 May 9. pii: canres.3556.2017.
    PubMed     Text format     Abstract available
    
    
    
37. LARIMER BM, Wehrenberg-Klee E, Dubois F, Mehta A, et al
    Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response.
    Cancer Res. 2017;77:2318-2327.
    PubMed     Text format     Abstract available
    
    
    
38. GUO G, Yu M, Xiao W, Celis E, et al
    Local Activation of p53 in the Tumor Microenvironment Overcomes Immune Suppression and Enhances Antitumor Immunity.
    Cancer Res. 2017;77:2292-2305.
    PubMed     Text format     Abstract available
    
    
    April 2017
39. NIMANONG S, Ostroumov D, Wingerath J, Knocke S, et al
    CD40 Signaling Drives Potent Cellular Immune Responses in Heterologous Cancer Vaccinations.
    Cancer Res. 2017;77:1918-1926.
    PubMed     Text format     Abstract available
    
    
    March 2017
40. 
    Correction: Differential Regulation of the Melanoma Proteome by eIF4A1 and eIF4E.
    Cancer Res. 2017;77:1505.
    PubMed     Text format    
    
    
    
41. KIRTANE AR, Sadhukha T, Kim H, Khanna V, et al
    Fibrinolytic Enzyme Cotherapy Improves Tumor Perfusion and Therapeutic Efficacy of Anticancer Nanomedicine.
    Cancer Res. 2017;77:1465-1475.
    PubMed     Text format     Abstract available
    
    
    
42. MAHNE AE, Mauze S, Joyce-Shaikh B, Xia J, et al
    Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy.
    Cancer Res. 2017;77:1108-1118.
    PubMed     Text format     Abstract available
    
    
    February 2017
43. STEINBERG SM, Shabaneh T, Zhang P, Martyanov V, et al
    Myeloid cells that impair immunotherapy are restored in melanomas which acquire resistance to BRAF inhibitors.
    Cancer Res. 2017 Feb 15. pii: canres.1755.2016.
    PubMed     Text format     Abstract available
    
    
    January 2017
44. ZHANG T, Xu M, Makowski MM, Lee C, et al
    SDHD promoter mutations ablate GABP transcription factor binding in melanoma.
    Cancer Res. 2017 Jan 20. pii: canres.0919.2016.
    PubMed     Text format     Abstract available
    
    
    
45. NEUBERT NJ, Tille L, Barras D, Soneson C, et al
    Broad and conserved immune regulation by genetically heterogeneous melanoma cells.
    Cancer Res. 2017 Jan 19. pii: canres.2680.2016.
    PubMed     Text format     Abstract available
    
    
    
46. SEKTIOGLU IM, Carretero R, Bulbuc N, Bald T, et al
    Basophils Promote Tumor Rejection via Chemotaxis and Infiltration of CD8+ T Cells.
    Cancer Res. 2017;77:291-302.
    PubMed     Text format     Abstract available
    
    
    November 2016
47. JOYCE CE, Yanez AG, Mori A, Yoda A, et al
    Differential regulation of the melanoma proteome by eIF4A1 and eIF4E.
    Cancer Res. 2016 Nov 22. pii: canres.1298.2016.
    PubMed     Text format     Abstract available
    
    
    September 2016
48. XIA T, Konno H, Barber GN
    Recurrent loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis.
    Cancer Res. 2016 Sep 28. pii: canres.1404.2016.
    PubMed     Text format     Abstract available
    
    
    
49. KIM M, Neznanov N, Wilfong CD, Fleyshman DI, et al
    Preclinical validation of a single-treatment infusion modality that can eradicate extremity melanomas.
    Cancer Res. 2016 Sep 28. pii: canres.2764.2015.
    PubMed     Text format     Abstract available
    
    
    
50. SATOW R, Nakamura T, Kato C, Endo M, et al
    ZIC5 drives melanoma aggressiveness by PDGFD-mediated activation of FAK and STAT3.
    Cancer Res. 2016 Sep 26. pii: canres.0991.2016.
    PubMed     Text format     Abstract available
    
    
    
51. CLARK CA, Gupta H, Sareddy GR, Pandeswara S, et al
    Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis and autophagy in ovarian cancer and melanoma.
    Cancer Res. 2016 Sep 26. pii: canres.0258.2016.
    PubMed     Text format     Abstract available
    
    
    
52. KLARQUIST J, Tobin K, Farhangi Oskuei P, Henning SW, et al
    CCL22 DIVERTS T REGULATORY CELLS AND CONTROLS THE GROWTH OF MELANOMA.
    Cancer Res. 2016 Sep 12. pii: canres.0618.2016.
    PubMed     Text format     Abstract available
    
    
    August 2016
53. TEH JL, Purwin TJ, Greenawalt EJ, Chervoneva I, et al
    An in vivo reporter to quantitatively and temporally analyze the effects of CDK4/6 inhibitor-based therapies in melanoma.
    Cancer Res. 2016 Aug 3. pii: canres.3384.2015.
    PubMed     Text format     Abstract available
    
    
    June 2016
54. ORSO F, Quirico L, Virga F, Penna E, et al
    miR-214 and miR-148b targeting inhibits dissemination of melanoma and breast cancer.
    Cancer Res. 2016 Jun 21. pii: canres.1322.2015.
    PubMed     Text format     Abstract available
    
    
    
55. BAKDASH G, Buschow SI, Gorris M, Halilovic A, et al
    Expansion of a BDCA1⁺CD14⁺ myeloid cell population in melanoma patients may attenuate the efficacy of dendritic cell vaccines.
    Cancer Res. 2016 Jun 20. pii: canres.1695.2015.
    PubMed     Text format     Abstract available
    
    
    
56. BOYLE SE, Fedele CG, Corbin V, Wybacz E, et al
    CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available
    
    
    
57. HU Y, Lu L, Xia Y, Chen X, et al
    Therapeutic efficacy of cancer stem cell vaccines in the adjuvant setting.
    Cancer Res. 2016 Jun 20. pii: canres.2664.2015.
    PubMed     Text format     Abstract available
    
    
    
58. ZHAO F, Sucker A, Horn S, Heeke C, et al
    Melanoma lesions independently acquire T-cell resistance during metastatic latency.
    Cancer Res. 2016 Jun 3. pii: canres.0008.2016.
    PubMed     Text format     Abstract available
    
    
    
59. SCHWARTZ H, Blacher E, Amer M, Livneh N, et al
    Incipient melanoma brain metastases instigate astrogliosis and neuroinflammation.
    Cancer Res. 2016 Jun 3. pii: canres.0485.2016.
    PubMed     Text format     Abstract available
    
    
    May 2016
60. HARBST K, Lauss M, Cirenajwis H, Isaksson K, et al
    Multi-region whole-exome sequencing uncovers the genetic evolution and mutational heterogeneity of early-stage metastatic melanoma.
    Cancer Res. 2016 May 23. pii: canres.3476.2016.
    PubMed     Text format     Abstract available
    
    
    
61. LAZAR I, Clement E, Dauvillier S, Milhas D, et al
    Adipocyte exosomes promote melanoma aggressiveness through fatty acid oxidation: a novel mechanism linking obesity and cancer.
    Cancer Res. 2016 May 23. pii: canres.0651.2016.
    PubMed     Text format     Abstract available
    
    
    
62. YAMADA K, Uchiyama A, Uehara A, Perera B, et al
    MFG-E8 drives melanoma growth by stimulating mesenchymal stromal cell-induced angiogenesis and M2 polarization of tumor-associated macrophages.
    Cancer Res. 2016 May 17. pii: canres.2812.2015.
    PubMed     Text format     Abstract available
    
    
    
63. HOLLANDER L, Guo X, Velazquez H, Chang J, et al
    Renalase expression by melanoma and tumor associated-macrophages promotes tumor growth through a STAT3-mediated mechanism.
    Cancer Res. 2016 May 9. pii: canres.1524.2015.
    PubMed     Text format     Abstract available
    
    
    April 2016
64. NEVALA WK, Buhrow SA, Knauer DJ, Reid JM, et al
    Antibody Targeted Chemotherapy for the Treatment of Melanoma.
    Cancer Res. 2016 Apr 28. pii: canres.3131.2015.
    PubMed     Text format     Abstract available
    
    
    
65. WEBER CE, Luo C, Hotz-Wagenblatt A, Gardyan A, et al
    miR-339-3p is a tumor suppressor in melanoma.
    Cancer Res. 2016 Apr 15. pii: canres.2932.2015.
    PubMed     Text format     Abstract available
    
    
    
66. MENGER L, Sledzinska A, Bergerhoff K, Vargas FA, et al
    TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors.
    Cancer Res. 2016;76:2087-93.
    PubMed     Text format     Abstract available
    
    
    
67. VASATURO A, Halilovic A, Bol KF, Verweij DI, et al
    T cell landscape in a primary melanoma predicts the survival of patients with metastatic disease after their treatment with dendritic cell vaccines.
    Cancer Res. 2016 Apr 11. pii: canres.3211.2015.
    PubMed     Text format     Abstract available
    
    
    March 2016
68. SHOSHAN E, Braeuer RR, Kamiya T, Mobley AK, et al
    NFAT1 directly regulates IL-8 and MMP-3 to promote melanoma tumor growth and metastasis.
    Cancer Res. 2016 Mar 24. pii: canres.2511.2015.
    PubMed     Text format     Abstract available
    
    
    
69. YOSHIDA A, Lee EK, Diehl JA
    Induction of therapeutic senescence in vemurafenib-resistant melanoma by extended Inhibition of CDK4/6.
    Cancer Res. 2016 Mar 17. pii: canres.2931.2015.
    PubMed     Text format     Abstract available
    
    
    
70. BUDINA-KOLOMETS A, Webster MR, Leu JI, Jennis M, et al
    HSP70 inhibition limits FAK-dependent invasion and enhances the response to melanoma treatment with BRAF inhibitors.
    Cancer Res. 2016 Mar 16. pii: canres.2137.2015.
    PubMed     Text format     Abstract available
    
    
    
71. KRUMM A, Barckhausen C, Kucuk P, Tomaszowski KH, et al
    Enhanced histone deacetylase activity in malignant melanoma provokes RAD51 and FANCD2 triggered drug resistance.
    Cancer Res. 2016 Mar 15. pii: canres.2680.2015.
    PubMed     Text format     Abstract available
    
    
    
72. CONERY AR, Centore RC, Spillane KL, Follmer NE, et al
    Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response.
    Cancer Res. 2016;76:1313-9.
    PubMed     Text format     Abstract available
    
    
    February 2016
73. NWANI NG, Deguiz ML, Jimenez B, Vinokour E, et al
    Melanoma cells block PEDF production in fibroblasts to induce the tumor-promoting phenotype of cancer-associated fibroblasts.
    Cancer Res. 2016 Feb 26. pii: canres.2468.2015.
    PubMed     Text format     Abstract available
    
    
    
74. BRENTVILLE VA, Metheringham RL, Gunn B, Symonds P, et al
    Citrullinated Vimentin Presented on MHC-II in Tumor Cells Is a Target for CD4+ T-Cell-Mediated Antitumor Immunity.
    Cancer Res. 2016;76:548-60.
    PubMed     Text format     Abstract available
    
    
    January 2016
75. BONYADI RAD E, Hammerlindl H, Wels C, Popper U, et al
    Notch4 signaling induces a mesenchymal-epithelial-like transition in melanoma cells to suppress malignant behaviors.
    Cancer Res. 2016 Jan 22. pii: canres.1722.2015.
    PubMed     Text format     Abstract available
    
    
    
76. TANAKA M, Shimamura S, Kuriyama S, Maeda D, et al
    SKAP2 Promotes Podosome Formation to Facilitate Tumor-Associated Macrophage Infiltration and Metastatic Progression.
    Cancer Res. 2016;76:358-69.
    PubMed     Text format     Abstract available
    
    
    
77. MEIER C, Hardtstock P, Joost S, Alla V, et al
    p73 and IGF1R Regulate Emergence of Aggressive Cancer Stem-like Features via miR-885-5p Control.
    Cancer Res. 2016;76:197-205.
    PubMed     Text format     Abstract available
    
    
    
78. PARK WY, Hong BJ, Lee J, Choi C, et al
    H3K27 Demethylase JMJD3 Employs the NF-kappaB and BMP Signaling Pathways to Modulate the Tumor Microenvironment and Promote Melanoma Progression and Metastasis.
    Cancer Res. 2016;76:161-70.
    PubMed     Text format     Abstract available
    
    
    December 2015
79. KOGUCHI Y, Hoen HM, Bambina SA, Rynning MD, et al
    Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab.
    Cancer Res. 2015;75:5084-92.
    PubMed     Text format     Abstract available
    
    
    November 2015
80. FENG Y, Pinkerton AB, Hulea L, Zhang T, et al
    SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.
    Cancer Res. 2015.
    PubMed     Text format     Abstract available
    
    
    
81. HERKERT B, Kauffmann A, Molle S, Schnell C, et al
    Maximizing the efficacy of MAPK-targeted treatment in PTENLOF/BRAFMUT melanoma through PI3K and IGF1R inhibition.
    Cancer Res. 2015 Nov 17. pii: canres.3358.2014.
    PubMed     Text format     Abstract available
    
    
    October 2015
82. HOLZEL M, Landsberg J, Glodde N, Bald T, et al
    A preclinical model of malignant peripheral nerve sheath tumor-like melanoma is characterized by infiltrating mast cells.
    Cancer Res. 2015 Oct 28. pii: canres.1090.2015.
    PubMed     Text format     Abstract available
    
    
    
83. HEILMANN S, Ratnakumar K, Langdon EM, Kansler ER, et al
    A Quantitative System for Studying Metastasis Using Transparent Zebrafish.
    Cancer Res. 2015;75:4272-82.
    PubMed     Text format     Abstract available
    
    
    September 2015
84. NOMAN MZ, Janji B, Hu S, Wu JC, et al
    Tumor-Promoting Effects of Myeloid-Derived Suppressor Cells Are Potentiated by Hypoxia-Induced Expression of miR-210.
    Cancer Res. 2015;75:3771-87.
    PubMed     Text format     Abstract available
    
    
    
85. MACLEOD AK, McLaughlin LA, Henderson CJ, Wolf CR, et al
    Activation status of the Pregnane X Receptor (PXR) influences Vemurafenib availability in humanized mouse models.
    Cancer Res. 2015 Sep 11. pii: canres.1454.2015.
    PubMed     Text format     Abstract available
    
    
    
86. BODOGAI M, Moritoh K, Lee-Chang C, Hollander CM, et al
    Immunosuppressive and Prometastatic Functions of Myeloid-Derived Suppressive Cells Rely upon Education from Tumor-Associated B Cells.
    Cancer Res. 2015;75:3456-65.
    PubMed     Text format     Abstract available
    
    
    
87. JI W, Li Y, He Y, Yin M, et al
    AIP1 Expression in Tumor Niche Suppresses Tumor Progression and Metastasis.
    Cancer Res. 2015;75:3492-504.
    PubMed     Text format     Abstract available
    
    
    August 2015
88. CHANDRAN SS, Paria BC, Srivastava AK, Rothermel LD, et al
    Tumor-Specific Effector CD8+ T Cells That Can Establish Immunological Memory in Humans after Adoptive Transfer Are Marked by Expression of IL7 Receptor and c-myc.
    Cancer Res. 2015;75:3216-26.
    PubMed     Text format     Abstract available
    
    
    
89. ADAMS GN, Rosenfeldt L, Frederick M, Miller W, et al
    Colon cancer growth and dissemination relies upon thrombin, stromal PAR-1 and fibrinogen.
    Cancer Res. 2015 Aug 3. pii: canres.0964.2015.
    PubMed     Text format     Abstract available
    
    
    July 2015
90. CAPPARELLI C, Rosenbaum S, Berman-Booty LD, Salhi A, et al
    ErbB3/ErbB2 complexes as a therapeutic target in a subset of wild-type BRAF/NRAS cutaneous melanomas.
    Cancer Res. 2015 Jul 23. pii: canres.2959.2014.
    PubMed     Text format     Abstract available
    
    
    
91. DONIA M, Andersen R, Kjeldsen JW, Fagone P, et al
    Aberrant expression of MHC Class II in melanoma attracts inflammatory tumor specific CD4+ T cells which dampen CD8+ T cell antitumor reactivity.
    Cancer Res. 2015 Jul 16. pii: canres.2956.2014.
    PubMed     Text format     Abstract available
    
    
    June 2015
92. HUANG JL, Urtatiz O, Van Raamsdonk CD
    Oncogenic G protein GNAQ induces uveal melanoma and intravasation in mice.
    Cancer Res. 2015 Jun 25. pii: canres.3229.2014.
    PubMed     Text format     Abstract available
    
    
    May 2015
93. HEBEISEN M, Schmidt J, Guillaume P, Baumgaertner P, et al
    Identification of Rare High-Avidity, Tumor-Reactive CD8+ T Cells by Monomeric TCR-Ligand Off-Rates Measurements on Living Cells.
    Cancer Res. 2015;75:1983-91.
    PubMed     Text format     Abstract available
    
    
    
94. GENG D, Kaczanowska S, Tsai A, Younger K, et al
    TLR5 Ligand-Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity.
    Cancer Res. 2015;75:1959-71.
    PubMed     Text format     Abstract available
    
    
    
95. BERTRAND F, Rochotte J, Colacios C, Montfort A, et al
    Blocking Tumor Necrosis Factor alpha enhances CD8 T cell-dependent immunity in experimental melanoma.
    Cancer Res. 2015 May 14. pii: canres.2524.2014.
    PubMed     Text format     Abstract available
    
    
    April 2015
96. SUN Z, Fourcade J, Pagliano O, Chauvin JM, et al
    IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells.
    Cancer Res. 2015;75:1635-44.
    PubMed     Text format     Abstract available
    
    
    
97. ALAMINO VA, Mascanfroni ID, Montesinos MM, Gigena N, et al
    Antitumor Responses Stimulated by Dendritic Cells Are Improved by Triiodothyronine Binding to the Thyroid Hormone Receptor beta.
    Cancer Res. 2015;75:1265-74.
    PubMed     Text format     Abstract available
    
    
    February 2015
98. CHEN S, Wang L, Fan J, Ye C, et al
    Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism.
    Cancer Res. 2015;75:519-31.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: